QNRX — Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 3
- Website: https://quoinpharma.com
Latest SEC filings for QNRX
- EFFECT — 2026-09-28
- S-3 — 2026-09-18
- D — 2026-09-10
- 8-K — 2026-08-20
- 8-K — 2026-08-14
- ARS — 2026-07-16
- 8-K — 2026-06-23
- 8-K — 2026-06-04
- 424B3 — 2026-06-02
- SCHEDULE 13G/A — 2026-05-15
Latest QNRX news
- — Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy (globenewswire.com)
Educational tool only — not investment advice.